Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von Merck Gesellschaft mbH.
Micardis(R) - Micardis Plus(R) - Verträglichkeit (9 Abbildungen)
Übersicht


Abb. 0: FÜR ÖSTERREICH: Weitere Informationen: Merck Gesellschaft mbH, Zimbagasse 5, 1147 Wien, Tel.: 01/576 00-0 Abb. 1: Verträglichkeit Abb. 2: Telmisartan - Placebo - Verträglichkeit Aktuelles Bild - Abb. 3: Telmisartan - Verträglichkeit Abb. 4: Telmisartan - HCTZ - Verträglichkeit Abb. 5: Verträglichkeitsprofil Abb. 6: Verträglichkeitsprofil Zum letzten Bild
Abbildung 3: Telmisartan - Verträglichkeit
A German post-marketing surveillance study followed 19,870 patients treated with telmisartan for 6 months.1 Data were not available for 2% of patients. Of the rest, 98.8% gave a global rating of tolerability of good or very good. Adverse events were reported by 1.9% of patients, the most frequent being headache (0.3%), dizziness (0.2%) and nausea (0.2%). Age, gender and comorbidities had no effect on global tolerability. 1. Michel MC, et al. Safety of telmisartan in patients with arterial hypertension. An open-label observational study. Drug Saf 2004; 27: 335–344.
 
Telmisartan - Verträglichkeit
Vorheriges Bild Nächstes Bild   


Abbildung 3: Telmisartan - Verträglichkeit
A German post-marketing surveillance study followed 19,870 patients treated with telmisartan for 6 months.1 Data were not available for 2% of patients. Of the rest, 98.8% gave a global rating of tolerability of good or very good. Adverse events were reported by 1.9% of patients, the most frequent being headache (0.3%), dizziness (0.2%) and nausea (0.2%). Age, gender and comorbidities had no effect on global tolerability. 1. Michel MC, et al. Safety of telmisartan in patients with arterial hypertension. An open-label observational study. Drug Saf 2004; 27: 335–344.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung